K. Squires

F. Hecht, J. Bartlett, K. Squires, 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

A novel codon insert in protease of clade B HIV type 1.

D. Richman, K. Squires, C. Ignacio, 2009, AIDS research and human retroviruses.

Population pharmacokinetics of stavudine (d4T) in patients with AIDS or advanced AIDS-related complex

K. Squires, K. Mayer, M. Dudley, 1995, Antimicrobial agents and chemotherapy.

Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK Study.

K. Mounzer, K. Squires, L. Bekker, 2013, AIDS research and human retroviruses.

Lipoprotein Changes in HIV-Infected Antiretroviral-Naïve Individuals after Starting Antiretroviral Therapy: ACTG Study A5152s Stein: Lipoprotein Changes on Antiretroviral Therapy.

R. Parker, C. Fichtenbaum, K. Squires, 2008, Journal of clinical lipidology.

K. Squires, E. Dejesus, N. Bellos, 2010, AIDS.

A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen.

S. Hammer, J. Mellors, K. Squires, 2010, HIV clinical trials.

Health needs of HIV-infected women in the United States: insights from the women living positive survey.

K. Squires, J. Aberg, S. Storfer, 2011, AIDS patient care and STDs.

Recruitment and retention of diverse populations in antiretroviral clinical trials: practical applications from the gender, race and clinical experience study.

K. Squires, J. Currier, J. Mrus, 2011, Journal of women's health.

Acquired resistance and granuloma formation in experimental visceral leishmaniasis. Differential T cell and lymphokine roles in initial versus established immunity.

K. Squires, C. Bogdan, H. Murray, 1992, Journal of immunology.

The acceptability of a directly-administered antiretroviral therapy (DAART) intervention among patients in public HIV clinics in Los Angeles, California

K. Squires, M. Witt, P. Weidle, 2007, AIDS care.

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial

P. Sax, K. Squires, H. Teppler, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Estimated glomerular filtration rates through 144 weeks on therapy in HIV-1-infected subjects receiving atazanavir/ritonavir and abacavir/lamivudine or simplified to unboosted atazanavir/abacavir/lamivudine

A. LaMarca, K. Tashima, K. Squires, 2015, HIV clinical trials.

Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women.

K. Squires, Jiahong Xu, B. Kapogiannis, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Safety and antiviral activity of combination therapy with zidovudine, zalcitabine, and two doses of interferon-alpha2a in patients with HIV. AIDS Clinical Trials Group Study 197.

D. Richman, M. Saag, K. Squires, 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.

M A Fischl, M D Hughes, S. Hammer, 1997, The New England journal of medicine.

Pharmacokinetic, safety, and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. AIDS Clinical Trials Group, and Cytomegalovirus Cooperative Study Group.

S. Spector, K. Squires, M. Jacobson, 1995, The Journal of infectious diseases.

Oral fluconazole therapy for patients with acquired immunodeficiency syndrome and cryptococcosis: experience with 22 patients.

K. Squires, J. Graybill, H. Murray, 1988, The American journal of medicine.

Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Acquired Immunodeficiency Syndrome Clinical Trials Group and Mycoses Study Group.

M. Saag, K. Squires, D. Bamberger, 1997, The American journal of medicine.

Fluconazole Compared with Ketoconazole for the Treatment of Candida Esophagitis in AIDS

L. Laine, K. Squires, F. Sattler, 1992, Annals of Internal Medicine.

Experimental visceral leishmaniasis: role of endogenous IFN-gamma in host defense and tissue granulomatous response.

R. Schreiber, M. McElrath, K. Squires, 1989, Journal of immunology.

A prospective study of genital herpes simplex virus type 2 infection in human immunodeficiency virus type 1 (HIV-1)-seropositive women: correlations with CD4 cell count and plasma HIV-1 RNA level.

Patty W. Wright, K. Squires, J. Gnann, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 5. Clinical features of cytomegalovirus retinitis at diagnosis. Studies of ocular complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group.

Paul E. Méndez, R. Haubrich, R. Brookmeyer, 1997, American journal of ophthalmology.

Oral ganciclovir for cytomegalovirus retinitis in patients with AIDS: results of two randomized studies.

K. Squires, 1996, AIDS.

Risk of opportunistic infection in the HAART era among HIV-infected Latinos born in the United States compared to Latinos born in Mexico and Central America.

K. Squires, M. Witt, A. Wohl, 2003, AIDS patient care and STDs.

Initiative to Decrease Cardiovascular Risk and Increase Quality of Care for Patients Living With HIV/AIDS Executive Summary

P. Wilson, R. Eckel, K. Yarasheski, 2008 .

An Introduction to Nucleoside and Nucleotide Analogues

K. Squires, 2000, Antiviral therapy.

Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy

T. Blaschke, L. Sheiner, K. Squires, 1997, Antimicrobial agents and chemotherapy.

Diabetes after aerosolized pentamidine.

K. Squires, J. P. Chen, R. Braham, 1991, Annals of internal medicine.

ATI-2173, a Novel Liver-Targeted Non-Chain-Terminating Nucleotide for Hepatitis B Virus Cure Regimens

K. Squires, A. Kolykhalov, Gregory R. Bluemling, 2020, Antimicrobial Agents and Chemotherapy.

Once-daily quadruple-drug therapy with adefovir dipivoxil, Lamivudine, Didanosine, and efavirenz in treatment-naive human immunodeficiency virus type 1-infected patients.

J. Tolson, D. Kuritzkes, K. Squires, 2002, The Journal of infectious diseases.

Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.

Christopher D Pilcher, Edward P Acosta, Daniel R Kuritzkes, 2004, The New England journal of medicine.

A Randomized Trial of Nelfinavir and Abacavir in Combination with Efavirenz and Adefovir Dipivoxil in HIV-1-Infected Persons with Virological Failure Receiving Indinavir

S. Hammer, J. Mellors, K. Squires, 2002, Antiviral therapy.

Occult hepatic opportunistic infection (OI) and highly active antiretroviral therapy (HAART) induced immune reconstitution: an important cause of jaundice in a patient with AIDS.

G. Kanel, K. Squires, A. Nowain, 2006, AIDS research and human retroviruses.

Severe Cholestatic Liver Injury Days After Initiating Antiretroviral Therapy in a Patient with AIDS: Drug Toxicity or Immune Reconstitution Inflammatory Syndrome?

G. Kanel, K. Squires, S. Pais, 2005, Digestive Diseases and Sciences.

A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients

M. Moroni, F. Antunes, J. Montaner, 2003, AIDS.

Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial.

C. Katlama, P. Sax, Y. Yazdanpanah, 2017, The lancet. HIV.

Tenofovir Disoproxil Fumarate in Nucleoside-Resistant HIV-1 Infection

M. Wulfsohn, K. Squires, A. Pozniak, 2003, Annals of Internal Medicine.

Background: Resistance to antiretroviral agents remains a lead- ing cause of treatment failure for patients infected with HIV-1.

M. Wulfsohn, K. Squires, A. Pozniak, 2003 .

Comparison of Once-Daily Atazanavir With Efavirenz, Each in Combination With Fixed-Dose Zidovudine and Lamivudine, As Initial Therapy for Patients Infected With HIV

J. Gatell, A. Vibhagool, A. Lazzarin, 2004, Journal of acquired immune deficiency syndromes.

Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s.

R. Parker, C. Fichtenbaum, K. Squires, 2008, Journal of the American College of Cardiology.

Evidence of immune reconstitution in antiretroviral drug-experienced patients with advanced HIV disease.

J. Phair, K. Squires, A. Landay, 2002, AIDS research and human retroviruses.

Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.

Christopher D Pilcher, Edward P Acosta, Daniel R Kuritzkes, 2006, JAMA.

Results of a Phase 2 Clinical Trial at 48 Weeks (AI424-007): A Dose-Ranging, Safety, and Efficacy Comparative Trial of Atazanavir at Three Doses in Combination with Didanosine and Stavudine in Antiretroviral-Naive Subjects

K. Squires, S. Schnittman, P. Piliero, 2003, Journal of acquired immune deficiency syndromes.

Brief Report: Phase IIa Safety Study of a Vaginal Ring Containing Dapivirine in Adolescent Young Women.

D. Szydlo, K. Squires, K. Bunge, 2020, Journal of acquired immune deficiency syndromes.

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus–1 Infection: Week 48 Results of the DRIVE-AHEAD Trial

P. Sax, K. Squires, C. Orkin, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.

P. Sax, K. Squires, P. Cahn, 2018, The lancet. HIV.

Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults.

William A. Lee, M. Wulfsohn, A. Zolopa, 2014, The Journal of antimicrobial chemotherapy.

Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Studies of ocular complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group.

Paul E. Méndez, R. Haubrich, J. Phair, 1995, Archives of internal medicine.

ARIES 144 Week Results: Durable Virologic Suppression in HIV-Infected Patients Simplified to Unboosted Atazanavir/Abacavir/Lamivudine

D. Ward, K. Squires, E. Dejesus, 2012, HIV clinical trials.

The Safety of Discontinuation of Maintenance Therapy for Cytomegalovirus (CMV) Retinitis and Incidence of Immune Recovery Uveitis Following Potent Antiretroviral Therapy

S. Spector, K. Squires, M. Jacobson, 2005, HIV clinical trials.

Indinavir, Efavirenz, and Abacavir Pharmacokinetics in Human Immunodeficiency Virus-Infected Subjects

S. Hammer, K. Squires, Hulin Wu, 2003, Antimicrobial Agents and Chemotherapy.

Interferon-γ and Mycobacterium avium-intracellulare Infection

L. Madoff, K. Squires, H. Murray, 1989 .

A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy.

M. Hirsch, B. Hirschel, S. Staszewski, 1999, The Journal of infectious diseases.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Cobicistat: A New Boost for the Treatment of Human Immunodeficiency Virus Infection

K. Squires, Jason J. Schafer, Bhavik M. Shah, 2013, Pharmacotherapy.

Bone Health and Human Immunodeficiency Virus Infection

K. Squires, Jason J. Schafer, Kristine Manlangit, 2013, Pharmacotherapy.

Coadministration of Indinavir and Nelfinavir in Human Immunodeficiency Virus Type 1-Infected Adults: Safety, Pharmacokinetics, and Antiretroviral Activity

D. Havlir, K. Squires, P. Deutsch, 2002, Antimicrobial Agents and Chemotherapy.

Brief Report: Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women

K. Squires, C. Kityo, A. Cheng, 2018, Journal of acquired immune deficiency syndromes.

Assessing darunavir/ritonavir-based therapy in a racially diverse population: 48-week outcomes from GRACE.

K. Squires, J. Currier, J. Mrus, 2012, Journal of the National Medical Association.

Sex-Based Outcomes of Darunavir–Ritonavir Therapy: The GRACE (Gender, Race, and Clinical Experience) Study

K. Squires, J. Currier, C. Zorrilla, 2010 .

Gender-specific considerations in the antiretroviral management of HIV-infected women

K. Squires, R. Clark, 2005, Expert review of anti-infective therapy.

Serum immunoglobulin G response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and risk-matched HIV-negative women.

Ann Duerr, Kelly Fox, K. Anastos, 2003, The Journal of infectious diseases.

Immune Reconstitution but Persistent Activation After 48 Weeks of Antiretroviral Therapy in Youth With Pre-Therapy CD4 >350 in ATN 061

K. Squires, J. Sleasman, B. Kapogiannis, 2015, Journal of acquired immune deficiency syndromes.

Daily Low-Dose Subcutaneous Interleukin-2 Added To Single- or Dual-Nucleoside Therapy in HIV Infection Does Not Protect Against CD4+ T-Cell Decline or Improve Other Indices of Immune Function: Results of a Randomized Controlled Clinical Trial (ACTG 248)

M. Lederman, R. Gelman, K. Squires, 2004, Journal of acquired immune deficiency syndromes.

Defect in the tissue cellular immune response: experimental visceral leishmaniasis in euthymic C57BL/6 ep/ep mice

M. McElrath, K. Squires, H. Murray, 1990, Infection and immunity.

Immunochemotherapy for visceral leishmaniasis: a controlled pilot trial of antimony versus antimony plus interferon-gamma.

K. Squires, H. Murray, J. Sherwood, 1993, The American journal of tropical medicine and hygiene.

Increased HIV infection rate among violent deaths: a mortuary study in the Republic of Congo

K. Squires, D. Berger, E. Dejesus, 2008, AIDS (London).

Once-daily antiretroviral therapies for HIV infection: Consensus statement of an Advisory Committee of the International Association of Physicians in AIDS Care

K. Squires, I. Frank, P. Tebas, 2002, Journal of the International Association of Physicians in AIDS Care.

Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES.

K. Squires, D. Margolis, G. E. Pakes, 2012, AIDS research and human retroviruses.

HIV policy: the path forward--a joint position paper of the HIV Medicine Association of the Infectious Diseases Society of America and the American College of Physicians.

David A. Fleming, D. Kuritzkes, M. Saag, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Screening and assessment of coronary heart disease in HIV-infected patients.

G. Mensah, A. Bolger, K. Squires, 2008, Circulation.

Impact of Tamoxifen on Vorinostat-Induced HIV Expression in Women on Antiretroviral Therapy (ACTG A5366:The MOXIE trial).

J. Karn, D. Kuritzkes, K. Squires, 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Integrase Inhibitors: A Novel Class of Antiretroviral Agents

K. Squires, Jason J. Schafer, 2010, The Annals of pharmacotherapy.

Influence of dapivirine vaginal ring use on cervicovaginal immunity and functional microbiome in adolescent girls

K. Squires, K. Bunge, J. Marrazzo, 2020, AIDS.

Risk perceptions after human papillomavirus vaccination in HIV-infected adolescents and young adult women.

G. Zimet, K. Squires, Jiahong Xu, 2012, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.

A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I)

K. Squires, P. Tebas, C. Cohen, 2000, AIDS.

The costs of HIV antiretroviral therapy adherence programs and impact on health care utilization.

Robert A Larsen, K. Squires, M. Witt, 2008, AIDS patient care and STDs.

M. Saag, K. Squires, J. Currier, 2011, AIDS research and treatment.

Patterns of plasma human immunodeficiency virus type 1 RNA response to antiretroviral therapy.

S. Hammer, D. Richman, D. Havlir, 2001, The Journal of infectious diseases.

Rhegmatogenous retinal detachment in patients with cytomegalovirus retinitis: The foscarnet-ganciclovir cytomegalovirus retinitis trial

Paul E. Méndez, R. Haubrich, A. Friedman, 1997 .

HIV Infection in Women

K. Squires, 1994 .

Prevalence of obstructive lung disease in HIV population: a cross sectional study.

R. Cavallazzi, B. Leiby, K. Squires, 2011, Respiratory medicine.

Gender differences in the diagnosis and treatment of HIV.

K. Squires, 2007, Gender medicine.

HIV infection in women: Do sex and gender matter?

K. Squires, K. Belden, 2008, Current infectious disease reports.

Summary Increase Quality of Care for Patients Living With HIV/AIDS: Executive State of the Science Conference: Initiative to Decrease Cardiovascular Risk and

R. Eckel, K. Yarasheski, M. Schambelan, 2008 .

A randomized trial of directly administered antiretroviral therapy and adherence case management intervention.

K. Squires, M. Witt, P. Weidle, 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Interferon-γ Treatment for Mycobacterium avium-intracellulare Complex Bacillemia in Patients with AIDS

K. Squires, H. Murray, D. Armstrong, 1992 .

Interferon-gamma treatment for Mycobacterium avium-intracellular complex bacillemia in patients with AIDS.

K. Squires, H. Murray, D. Armstrong, 1992, Journal of Infectious Diseases.

Interferon-gamma and Mycobacterium avium-intracellulare infection.

L. Madoff, K. Squires, H. Murray, 1989, Journal of Infectious Diseases.

The feasibility of a community-based directly administered antiretroviral therapy program.

K. Squires, M. Witt, P. Weidle, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Widespread intradermal accumulation of mononuclear leukocytes in lepromatous leprosy patients treated systemically with recombinant interferon gamma

K. Squires, C. Nathan, C. K. Job, 1990, The Journal of experimental medicine.

Once-Daily Doravirine for Initial Treatment of Adults Living With HIV-1: An Integrated Safety Analysis.

P. Sax, K. Squires, P. Cahn, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression

D. Kuritzkes, K. Squires, B. Schackman, 2007, AIDS.

Association of Efavirenz Hypersusceptibility with Virologic Response in ACTG 368, a Randomized Trial of Abacavir (ABC) in Combination with Efavirenz (EFV) and Indinavir (IDV) in HIV-Infected Subjects with Prior Nucleoside Analog Experience

S. Hammer, K. Squires, M. Fischl, 2008, HIV clinical trials.

Qualitative Study on the Acceptability of and Adherence to a Vaginal Ring for HIV Prophylaxis Among Adolescent Girls

K. Squires, K. Bunge, K. Mayer, 2021, Journal of acquired immune deficiency syndromes.

Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks

K. Squires, S. Walmsley, G. E. Pakes, 2017, HIV/AIDS.

Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study

M. Johnson, K. Squires, J. Absalon, 2010, The Journal of antimicrobial chemotherapy.

Multidrug-experienced HIV-1-infected women demonstrated similar virological and immunological responses to tipranavir/ritonavir compared with men

P. Easterbrook, K. Squires, S. Walmsley, 2009, AIDS.

Comparative analysis of commercial assays for the detection and quantification of Human Immunodeficiency Virus Type 1 (HIV-1) RNA in plasma from patients infected with HIV-1 subtype C.

J. Raper, K. Squires, G. Aldrovandi, 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Reply to Smith-Rohrberg and Altice

K. Squires, M. Witt, P. Weidle, 2006 .

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

B. Gazzard, C. Katlama, K. Ruxrungtham, 2004, The Lancet.

Treating HIV infection and AIDS in women.

K. Squires, 2003, The AIDS reader.

Do type and duration of antiretroviral therapy attenuate liver fibrosis in HIV-hepatitis C virus-coinfected patients?

G. Kanel, K. Squires, Chun‐Hsiang Wang, 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Clinical Infectious Disease: HIV-1 Infection: Antiretroviral Therapy

K. Squires, D. Neofytos, 2008 .

HIV and Pregnancy (Case 17)

K. Squires, K. Belden, 2010 .

Frequency of anovulation and early menopause among women enrolled in selected adult AIDS clinical trials group studies.

K. Squires, K. Mulligan, C. Benson, 2001, The Journal of infectious diseases.

Atazanavir—A Once-daily HIV Protease Inhibitor That Does Not Cause Dyslipidemia in Newly Treated Patients: Results from Two Randomized Clinical Trials

Adriano Lazzarin, J. Gatell, A. Lazzarin, 2004, Journal of the International Association of Physicians in AIDS Care.

Factors influencing the acceptance of changes in antiretroviral therapy among HIV-1-infected patients.

L. Markson, K. Squires, J. Dehovitz, 2007, AIDS patient care and STDs.

Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s.

D. Kuritzkes, K. Squires, C. Shikuma, 2007, The Journal of infectious diseases.

A novel codon insert in protease of clade B HIV type 1.

D. Richman, K. Squires, C. Ignacio, 2009, AIDS research and human retroviruses.

Interleukin-2 treatment, interferon-γ induction, and AIDS monocyte activation

K. Squires, H. Murray, J. Depamphilis, 1992 .

An Adherence-Focused Case Management Intervention for HIV-Positive Patients in a Public Care Setting

K. Squires, M. Witt, P. Weidle, 2009 .

Hiv/aids -research and Palliative Care Dovepress Response by Gender of Hiv-1-infected Subjects Treated with Abacavir/lamivudine plus Atazanavir, with or without Ritonavir, for 144 Weeks on Behalf of the Aries Study Team

K. Squires, S. Walmsley, G. E. Pakes, 2022 .

Predictors of Virologic and Clinical Outcomes in HIV-1Infected Patients Receiving Concurrent Treatment with Indinavir, Zidovudine, and Lamivudine: AIDS Clinical Trials Group Protocol 320

S. Hammer, M. Hughes, S. Spector, 2001, Annals of Internal Medicine.

Impact of Dapivirine and Placebo Vaginal Rings on the Microbiota of Adolescent, Lactating, and Postmenopausal Females.

L. Meyn, K. Squires, K. Bunge, 2021, The Journal of infectious diseases.

543. An Integrated Safety Analysis Comparing Once-Daily Doravirine (DOR) to Darunavir+Ritonavir (DRV+r) and Efavirenz (EFV) in HIV-1-Infected, Antiretroviral Therapy (ART)-Naïve Adults

P. Sax, J. Gatell, K. Squires, 2018, Open Forum Infectious Diseases.

LB1. Doravirine/Lamivudine/Tenofovir DF Continues to Be NonInferior to Efavirenz/Emtricitabine/Tenofovir DF in Treatment-Naïve Adults With HIV-1 Infection: Week 96 Results of the DRIVE-AHEAD Trial

P. Sax, K. Squires, H. Teppler, 2018, Open Forum Infectious Diseases.

Integrase Inhibitors: A Novel Class of Antiretroviral Agents

K. Squires, Jason J. Schafer, 2010, The Annals of pharmacotherapy.